Posted by CaptainAmerica1967 on December 1, 2011, at 3:23:24
In reply to Re: Alkernes 5461 TRD buprenorphine plus ? in phase II, posted by uncouth on November 30, 2011, at 21:41:35
I haven't even looking for the clinicl trial on clinical trials dot gov for ALKS 5461 (buprenorphine plus ALKS 33) but I looked again at Alermes website, and it's just finished phase 1 (no press release) but can only find information for 1/2 of phase 1
Pipeline for Alkermes Company:
http://www.alkermes.com/Research-and-Development/Pipeline, and it say to go clinical trials dot com.
"ALKS 5461" is the combination buprenorphine plus that of ALKS 33 and buprenorphine. ALKS 33 has already finished phase II and going to phase 3. ALKS 33 is going to be indicated for alcohol addiction but didn't pass for binge eating.
http://www.drugs.com/clinical_trials/alkermes-announces-results-phase-2-study-alks-33-binge-eating-disorder-12083.htmlJust looked at clinical trials for company Alkermes (ALKS). Not sure if any conclusions yet except that the key will be the ALKS 33 study as I already know buprenoprhine works for me (hope it works for the study) and from what I can see on this study, they exclude anyone allergic to naltrexone making me think it's low dose naltrexone which is already used by psychiatrist given at night to increase natural levels of endorphins because the receptor overcome the small dose therefore increasing endorphins. Low Dose Naltrexone is used off lable for many autoimmune diseases like Huntington's, MS, etc which good success.
Here's all Alkerme's studies on clinical trial:
http://clinicaltrials.gov/ct2/results?term=ALKS
I've heard on the news recently and TV an advertisements for opioid inducted constipation.
poster:CaptainAmerica1967
thread:1003842
URL: http://www.dr-bob.org/babble/20111120/msgs/1004048.html